• The role of Raptor in lymphocytes differentiation and function 

  Tang, J; Yang, L; Guan, F; Miller, H; Camara, NOS; James, LK; Benlagha, K; Kubo, M; Heegaard, S; Lee, P (2023-05-22)

• Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies. 

  Zeng, G; Koffas, A; Mak, L-Y; Gill, US; Kennedy, PTF (2023-06)

  BACKGROUND & AIMS: Antivirals represent the mainstay of chronic hepatitis B treatment given their efficacy and tolerability, but rates of functional cure remain low during long-term therapy. Treatment discontinuation has ...

• COVID-19 Hampered Diagnosis of TB Infection in France, Italy, Spain and the United Kingdom 

  Garcia-Garcia, J-M; Blanc, F-X; Buonsenso, D; Centis, R; Codecasa, LR; D'Ambrosio, L; Goletti, D; Gualano, G; Kunst, H; Pontali, E (2022-11)

• Assessment of Platelet Function by High-Throughput Screening Light Transmission Aggregometry: Optimul Assay. 

  Chan, MV; Lordkipanidzé, M; Warner, TD (2023)

  Platelet function testing is critical in the diagnosis of bleeding disorders and allows monitoring of antiplatelet therapy. The gold standard assay, light transmission aggregometry (LTA), was developed 60 years ago and ...

• Oral Presentation No. 093 Assessing different noncoding RNAs as markers of platelet reactivity 

  Gutmann, C; Barwari, T; Schulte, C; Singh, B; Theofilatos, K; Joshi, A; Zampetaki, A; Chan, MV; Armstrong, PC; Kiechl, S (2022-10-21)

• Vitamin D supplementation to prevent tuberculosis infection in South African schoolchildren: multicentre phase 3 double-blind randomised placebo-controlled trial (ViDiKids). 

  Middelkoop, K; Stewart, J; Walker, N; Delport, C; Jolliffe, DA; Coussens, AK; Nuttall, J; Tang, JCY; Fraser, WD; Griffiths, CJ (2023-05-19)

  BACKGROUND: Vitamin D metabolites induce innate antimycobacterial responses in vitro. Observational studies consistently report independent associations between vitamin D deficiency and increased susceptibility to Mycobacterium ...

• Management of nontuberculous mycobacteria-pulmonary disease: Results from the first UK survey of clinical practice. 

  Malhotra, AM; Bryant, S; Kunst, H; Haworth, CS; Lipman, M; NTM Network UK (2023-04-18)

• Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. 

  Sax, PE; Arribas, JR; Orkin, C; Lazzarin, A; Pozniak, A; DeJesus, E; Maggiolo, F; Stellbrink, H-J; Yazdanpanah, Y; Acosta, R (2023-05)

  BACKGROUND: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen recommended for HIV-1 treatment. The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: ...

• Renal Function Underpins the Cyclooxygenase-2: Asymmetric Dimethylarginine Axis in Mouse and Man 

  Ferreira, P; Vaja, R; Lopes-Pires, M; Crescente, M; Yu, H; Nüsing, R; Liu, B; Zhou, Y; Yaqoob, M; Zhang, A (2023-01-01)

  Introduction: Through the production of prostacyclin, cyclooxygenase (COX)-2 protects the cardiorenal system. Asymmetric dimethylarginine (ADMA), is a biomarker of cardiovascular and renal disease. Here we determined the ...

• Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls 

  Zheng, B; Vivaldi, G; Daines, L; Leavy, OC; Richardson, M; Elneima, O; McAuley, HJC; Shikotra, A; Singapuri, A; Sereno, M (2023-01-01)

  Background: The risk factors for recovery from COVID-19 dyspnoea are poorly understood. We investigated determinants of recovery from dyspnoea in adults with COVID-19 and compared these to determinants of recovery from ...

• What can we learn from senescent platelets, their transcriptomes and proteomes? 

  Allan, HE; Vadgama, A; Armstrong, PC; Warner, TD (2023-12-31)

• SARS-CoV-2 Spike protein activates TMEM16F-mediated platelet procoagulant activity 

  Cappelletto, A; Allan, HE; Crescente, M; Schneider, E; Bussani, R; Ali, H; Secco, I; Vodret, S; Simeone, R; Mascaretti, L (2023-01-04)

• Determinants of antibody responses to primary courses and booster doses of SARS-CoV-2 vaccines in 9,101 UK adults 

  Jolliffe, DA; Faustini, SE; Holt, H; Talaei, M; Vivaldi, G; Richter, AG; Shaheen, SO; Martineau, AR (2022-09-04)

• RISK FACTORS FOR BREAKTHROUGH COVID-19 IN 14,713 UK ADULTS AFTER PRIMARY AND BOOSTER DOSES OF SARS-COV-2 VACCINES 

  Vivaldi, G; Jolliffe, DA; Holt, H; Talaei, M; Tydeman, F; Shaheen, SO; Martineau, AR (2022-11)

• Rebound in asthma exacerbations following relaxation of COVID-19 restrictions: a longitudinal population-based study (COVIDENCE UK) 

  Tydeman, F; Pfeffer, PE; Vivaldi, G; Holt, H; Talaei, M; Jolliffe, D; Davies, G; Lyons, RA; Griffiths, C; Kee, F (2022-11-24)

• Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination 

  Holt, H; Jolliffe, DAA; Talaei, M; Faustini, S; Vivaldi, G; Greenig, M; Richter, AGG; Lyons, RAA; Griffiths, CJJ; Kee, F (2023-02-25)

• VITAMIN D TO PREVENT COVID-19 OR OTHER ACUTE RESPIRATORY INFECTIONS: PHASE 3 RANDOMISED CONTROLLED TRIAL (CORONAVIT) 

  Jolliffe, DA; Holt, H; Talaei, M; Sheikh, A; Griffiths, CJ; Shaheen, SO; Relton, C; Martineau, AR (2022-11)

• Vitamin D to prevent COVID-19 or other acute respiratory infections: phase 3 randomised controlled trial (CORONAVIT) 

  Jolliffe, DA; Holt, H; Talaei, M; Sheikh, A; Griffiths, CJ; Shaheen, SO; Relton, C; Martineau, AR (2022-09-04)

• Recruitment and Residence of Intestinal T Cells - Lessons for Therapy in Inflammatory Bowel Disease 

  Gordon, H; Rodger, B; Lindsay, JO; Stagg, AJ (2023-02-20)

• Mpox in people with advanced HIV infection: a global case series 

  Mitja, O; Alemany, A; Marks, M; Mora, JIL; Rodriguez-Aldama, JC; Silva, MST; Herrera, EAC; Crabtree-Ramirez, B; Blanco, JL; Girometti, N (2023-03-18)

View more